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Polymerase chain reaction (PCR) is a technique that can amplify a specific DNA segment in vitro using
two site specific primers that hybridise to opposite DNA strands. The method produces large amounts of
specific DNA from a complex DNA template in a single enzymatic reaction within a matter of hours.
Reaction mixture contains a double helix DNA, two target specific primers, dNTPs, a DNA polymerase
and a Mg2+ containing buffer. PCR is carried out in three distinct steps i.e. denaturation step, annealing
step and extension step, which are repeated many times. The efficiency of PCR is measured in terms of
its specificity, yield and fidelity. Most of the disease pathologies are associated with an altered gene
expression leading to a resultant increase or decrease in the activity of cellular proteins. PCR can be
employed to quantify alterations in cellular mRNA encoding for such proteins. These proteins may serve
as novel target sites for therapeutic intervention. This modified form of PCR is termed as reverse
transcriptase PCR (RT-PCR). In situ PCR, another modified form of PCR, not only permits the quantification
of mRNA but also the exact localisation of mRNA changes in a particular cell type in a given tissue. PCR
has also been employed to amplify a family of related genes using degenerate oligo nucleotide primers
(DOP). This strategy is known as homology screening or DOP-PCR and has successfully expanded
several gene families such as cyclins and cyclin-dependent kinases. Besides these application of PCR
in pharmacology, it also serves as a useful diagnostic tool.




Recombinant DNA technology has emerged as a
powerful tool for in vivo DNA amplification in dividing
cells of micro-organisms. However, the technique is
labour intensive and time consuming. In 1984, Karry
Mullis while working with human-β-globin at Cetus
Corporation developed an in vitro method for DNA
amplification1. This technique was termed as
polymerase chain reaction (PCR). PCR is an
enzymatic technique to amplify a specific DNA seg-
ment in vitro using two site specific primers that hy-
bridise to complimentary DNA strands. The method
produces large amount of specific DNA from a com-
plex DNA template in a single enzymatic reaction
within a matter of hours. Therefore, PCR is much
faster and simpler procedure as compared to
recombinant DNA technology. Moreover, PCR is a
highly sensitive technique which can amplify even
picograms of DNA and starting DNA need not be
pure or free from contamination of cell components.
On the other hand, PCR amplifies DNA in a cell free
system and this has greatly simplified subsequent
cloning, analysis and modification of DNA. These ad-
vantages of PCR are reflected in an exponential in-
crease in its use in the diverse scientific fields. The
present review intends to describe the basic meth-
odology of PCR with its possible application to phar-
macological sciences.
Principle and methodology
A typical PCR protocol is carried out in a reaction
mixture of 20-100 µl, either in individual tubes or
multiwell plates. Reaction mixture contains a double
helix DNA, two target specific primers, deoxynucleo-
tide triphosphates (dNTPs), a DNA polymerase and
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a Mg2+ containing buffer. Mg2+ ions are required as a
cofactor for DNA polymerase. Primers are 17-30 base
containing oligonucleotides that hybridise to 5' end
of regions flanking the target DNA sequence. PCR
is carried out in three distinct cycles which are re-
peated many times. Each cycle begins with a dena-
turation step in which the reaction mixture is heated
to 92-96oC to denature the double stranded DNA.
Time required to denature DNA depends on its com-
plexity, geometry of tubes and volume of reaction
mixture. For G≡C rich DNA sequence, addition of
glycerol, longer denaturation time and use of
nucleotide analogues has been reported to improve
yield of PCR3. Insufficient heating during denatura-
tion step is the most common cause of PCR failure.
The denaturation step is followed by annealing step
in which the primers are allowed to hybridise to their
complementary DNA sequences. The temperature
of this step varies from 37oC to 65oC depending on
the homology of the primers for the target sequence
and the composition of the primers. Since the prim-
ers are present in high concentration and are short
in length, they hybridize to their target sequence at a
much higher rate than the complementary strands
of the target DNA. In the final step, the annealed
primer is extended at its 3' hydroxy position by a DNA
polymerase. This three step cycle is repeated many
times until a sufficient amount of target DNA is pro-
duced. Each extension product generated in one PCR
cycle can serve as a template for extension in the
next cycle (Figure 1). Therefore, PCR product in-
creases exponentially as a function of the cycle
number. Earliest PCR experiments employed
klenow's fragment of E.coli DNA polymerase for DNA
extension step2. This enzyme has optimal activity at
37oC and often amplifies non-specific DNA target
products. Moreover, the enzyme gets inactivated at
higher temperature, therefore fresh enzyme has to
be added after each denaturation cycle. Later on, a
heat resistant DNA polymerase named as Taq
polymerase, was isolated from a thermophilic bacte-
rium Thermus aquaticus3. Several thermostable DNA
polymerases have now been isolated from various
other thermophilic bacteria (Table 1). Unlike klenow
fragment, these enzymes escape inactivation dur-
ing the denaturation cycle. Therefore, they need to
be added just once in the reaction mixture at the be-
ginning. This has allowed automation of PCR using
programmable machines named as thermocyclers.
If the annealing step is carried out at low tempera-
ture, primers may hybridize to non-specific targets
due to looping out of primers at low temperature.
Thermostable polymerases allow annealing and ex-
tension at an elevated temperature, therefore am-
plify target DNA by minimising primer mismatch.
Moreover, these polymerases allow amplification of
much bigger DNA fragments as compared to 400bp
with klenow's fragments4.
 The efficiency of PCR is measured in terms of its
specificity, yield and fidelity.
Optimization of PCR specificity
Specificity is achieved by designing primers of suffi-
cient length so that their sequence is virtually unique
in the genome. Various additives such as DMSO1,5,6
(1-10%), glycerol5-7 (5-20%), non-ionic detergents,
formamide5,6,8 (1.25-10%), bovine serum albumin5-7
(10-100 µg/ml) and polyethyleneglycol 6000 (5-
15%)9,10 can be incorporated into the reaction to in-
crease PCR  specificity. It has been proposed that
these reagents enhance specificity by lowering strand
separation temperature of DNA. At lower tempera-
ture, looping out of primers promotes formation of
primer template complexes that are not perfectly
matched and allow extension of mismatched target.
This can be avoided by hot start PCR11-13. Use of
klenow's fragment does not permit hot start and ac-
counts for non-specific DNA amplification as was
mentioned above.
PCR specificity can also be enhanced by the use of
nested PCR. In this technique, products from first
PCR amplification are subsequently amplified using
a second set of primers which flank the same target
site but internal to original primers. Any spurious
product amplified in the first reaction by mispriming are
unlikely to possess the identical nucleotide sequence
for the internal primer. Therefore, only genuine product
will be amplified in the second reaction1,13-16.
Optimization of PCR yield
To maximize PCR yield, primers and dNTPs should
always be present in molar excess. However, if the
quantity of primers and dNTPs is excessively large,
PCR is prone to low specificity and fidelity respec-
tively. The average yield of a PCR protocol can be
described by the following equation17:
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Table 1. Various thermostable DNA polymerases.
Enzyme Source Temperature (oC) General applications
TaqTM Thermus aquaticus 70-80 Broad range
Stoffel Thermus aquaticus 70-80
  FragmentTM
TthTM Thermus thermophilus 110-120 RT-PCR
Tli/VentTM Thermococcus litoralis 72-80 High fidelity PCR, LM PCR
pfuTM Pyrococcus furiosus 72-80 High fidelity PCR, DNA sequencing
BstTM Bacillus stearothermophilus 60-65 High sensitivity
Sac Sulfolobus acidocaldarius 70-80 DNA sequencing
Tac Thermoplasma acidophilum 65 AT rich DNA PCR
Tfl/TubTM Thermus flavus 70 Large template DNA PCR
Tru Thermus ruber 50 DNA sequencing
Tsp Thermotoga sp 80 DNA sequencing
Mth Methanobacterium 65 DNA sequencing
thermoautotrophicum
TM: Trademark
N=n(1+E)c     where   N= final amount of target DNA
n=initial amount of DNA
E=efficiency of amplification
c=number of PCR cycles
However, the yield of PCR varies significantly de-
pending upon the nature of the target sequence,
primer sequence and reaction conditions18,19.
Optimization of PCR fidelity
PCR infidelity, defined as rate of nucleotide
misincorporation, has been the subject of exhaus-
tive investigation. Taq polymerase lacks 3'-5'
exonuclease proofreading activity and has a high
error rate in PCR. Nucleotide incorporation in PCRs
employing Taq polymerase is further dependent upon
dNTP concentration. Certain other thermostable
DNA polymerases such as Pfu or T4 polymerase
have 3'-5' proofreading activity and are reported to
improve f idel i ty18,19. In general, rate of
misincorporation can be reduced by minimizing the
annealing or extention time, reducing dNTP and Mg2+
ion concentration and maximizing annealing tempera-
ture20. Unfortunately, the reaction conditions that mini-
mize misincorporation also reduce PCR yield.
Analysis of PCR Product
(a) Electrophoresis
Agarose gel (typically 1-1.5% w/v) electrophoresis
followed by staining with ethidium bromide represents
the simplest and most common method to analyse
PCR product. PCR product is of a defined length.
The size of PCR product may be calculated by si-
multaneous running of DNA molecular weight marker
on the agarose gel. Excess primers may appear as
diffuse bands close to the leading edge of the gel21.
(b) Southern blotting and hybridisation
After electrophoresis, PCR amplified DNA template
is transferred (blotted) onto a nitrocellulose or nylon
membrane. Blotted DNA is denatured to single strand
and fixed onto the membrane by heating at 80oC or
by U.V. crosslinking. The membrane is then placed
in a solution contaning labelled (Radioactive or
flouresent) complementary single stranded
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Figure 1. Schematic representation of steps involved in PCR.
oligonucleotide known as probe. Hybridisation oc-
curs between the lablled probe and complementary
single stranded sequence present on membrane. The
position of probe can be visualised by autoradio-
graphy or chemilumnisense22.
Modified versions of PCR
The basic technique of PCR has been modified in
several ways which has broadened its applications.
The detailed discussion of the modifications of PCR
techniques is beyond the scope of this review and
therefore, they are being mentioned only in brief.
Allele specific PCR is employed to detect point
mutations responsible for genetic disorders. Primers
are designed to anneal at the site which is probable
to undergo mutation. Therefore, primers will not an-
neal to this site if it has suffered from mutation and
DNA amplification will not take place in case of mu-
tated genes23. Inverse PCR can be used to amplify
the unsequenced DNA template that lie adjacent to
a core DNA sequence  for which the primer sequence
is already known24-26. Pan handle PCR allows the
amplification of DNA when the sequence for primer
design is known only on one end of target DNA se-
quence27,28. Race PCR is a technique to obtain full
length cDNA while starting from limited nucleotide
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sequence. PCR has also been employed to intro-
duce point mutations in the target DNA. This tech-
nique termed as PCR mutagenesis, employs prim-
ers which are not exactly complementary to their tar-
get sequence but still undergo annealing under ap-
propriate reaction conditions29-31. Ligation-mediated
PCR (LM PCR) is an extremely sensitive technique
to map single-stranded DNA breaks, DNA
methylation and nucleosome position. Therefore, the
technique is quite useful for toxicological studies32.
Arbitraily primed PCR (AP PCR) or DNA amplifica-
tion finger printing is a technique which can be em-
ployed to identify genotypes or different strains of a
single species. The technique is of great importance
in diagnosis of microbial strains. In AP PCR, strin-
gency of primer annealing is sufficiently lowered.
Therefore, primer binds to more than one target sites
in the DNA and amplifies more than one PCR
products. This set of PCR products is specific and
reproducible. After electrophoresis, it may be viewed
as finger print to identify source DNA33.
Applications of PCR in pharmacological research
1. Quantification of gene expression
Discovery of a new target site for therapeutic inter-
vention is every pharmacologist`s dream. Most of the
disease pathologies are associated with an altered
gene expression leading to an increase or decrease
in the activity of cellular proteins. PCR can be em-
ployed to detect very small alterations in cellular
mRNA encoding for such proteins. This modified form
of PCR is termed as reverse transcriptase PCR (RT-
PCR). In this technique, cellular RNA is initially re-
verse transcribed to cDNA in a reaction mixture con-
taining oligo dT primers, a viral reverse transcriptase,
all four dNTPs and MgCl2 containing buffer. The cDNA
thus generated, can be amplified by PCR using prim-
ers specific to a particular mRNA. The final amount
of PCR product generated from mRNA, depends on
the starting amounts of mRNA and efficiency of the
reverse transcription and PCR reactions. In order to
rule out the variability due to later two factors, two
basic methods have been employed to quantitative
mRNA using RT-PCR.
Noncompetitive  RT-PCR
In this method, a known quantity of standard DNA
template is added exogenously. Standard DNA and
target cDNA are co-amplified simultaneously using
RT-PCR. From the ratio of amplified DNA, absolute
value of target cDNA can be calculated. Alternatively,
an endogenous gene transcript with high tissue ex-
pression can act as an internal standard. Such gene
transcripts are termed as "House keeping genes".
Genes for β-actin, HPRT and GAPDH are some of
the examples of house keeping genes routinely em-
ployed as internal standards34-37. However, the quan-
tification relies on the empirical assumption that effi-
ciency of PCR is same for target cDNA and stand-
ard DNA or endogenous gene. Therefore, this method
of mRNA quantification is less accurate.
Competitive  RT-PCR
In contrast to non-competitive RT-PCR, this method
employs an external DNA standard that closely mim-
ics target cDNA with respect to primer binding and
other PCR variables38-40. Therefore, standard and tar-
get cDNA get amplified with the same efficiency.
However, the method doesn't take into account the
efficiency of reverse transcription reaction. To over-
come this limitation, samples have been spiked with
a known quantity of mRNA transcripts which are re-
verse transcribed and amplified in a manner analo-
gous to target mRNA. This method is reported to yield
better results.
RT-PCR has been employed to quantitate the mRNA
for many proteins. PGI2 synthase41, Cox 241, iNOS42,43,
AT1 receptors44, peroxisome proliferation activated
receptors45, matrix metalloprotinases (MMP-1, MMP-
3 and MMP-9)46, cGMP dependent protein kinase47,
cardiac background K+ channel48, human renin49,
NPY and NPY receptors50, endothelial leptin recep-
tors51, human P2X7  receptor subtype52 mRNA arejust a few to name. Intrinsic expression of multidrug
resistance gene is a major impediment in the treat-
ment of cancer by chemotherapy. The MDR pheno-
type may be caused by expression of transporters
of P glycoprotein family or multidrug resistance pro-
tein family53. Expression of MDR transporters serves
as an important predictor for clinical prognosis of
cancer54. RT-PCR has been extensively employed to
quantify the expression of MDR transporters in
several types of carcinomas53-57.
2. Cellular localisation of gene expression
Although RT-PCR is a highly sensitive technique to
detect small alteration in gene expression, it does
not permit the cellular localization of such gene
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alteration. Homogenized tissue samples employed
for RT-PCR mostly consist of heterogeneous group
of cells. Therefore, in a given pathological condition
it is difficult to ascribe the mRNA expression altera-
tion to a particular cell type. In situ PCR overcomes
this short coming of RT-PCR. In this technique, a tis-
sue section is fixed on a glass slide in formalin58.
Cellular proteins are digested on the slide with the
help of pepsin, trypsin  or proteinase K. DNA is di-
gested with help of DNAase. The total messenger
RNA is reversed transcribed to cDNA as described
in RT-PCR by putting all the reagents on slide. The
cDNA thus generated is amplified using two specific
set of primers, Taq polymerase and streptavidin con-
taining dNTPs. Finally, this slide is stained with nu-
clear fast red stain and viewed under microscope.
3. Identification of gene families
PCR has been employed to amplify a family of re-
lated genes using degenerate oligo nucleotide prim-
ers (DOP). DOP are mixture of primers designed
around a conserved domain of a gene family but with
alternative nucleotides at certain positions58. There-
fore, these primers will bind to closely related DNA
sequences in the genome. This strategy is known as
homology screening or DOP-PCR and has success-
fully expanded several gene families such as cyclins
and cyclin-dependent kinases58.
PCR has also revolutionised the detection of genetic
disorders such as haemoglobinopathies, X-linked
disorders, cystic fibrosis, cancers such as acute
myeloid leukemia, chronic myeloid leukemia and in-
fectious disorders such as tuberculosis, HIV and
hepatitis B. However, this use of PCR is more of a
diagnostic rather than pharmacological interest.
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